OBJECTIVE: The proliferation of vascular smooth muscle cells (VSMCs) plays a crucial role in vascular diseases, such as atherosclerosis and restenosis, after percutaneous coronary intervention. Many studies have shown that estrogen inhibits VSMC proliferation in response to vascular injury in the mouse carotid injury model. However, the mechanisms that mediate these effects remain unclear. Here, we investigated the mechanisms by which estrogen inhibits VSMC proliferation. APPROACH AND RESULTS: We established a novel transgenic mouse line, referred to as the disrupting peptide mice, in which rapid estrogen receptor (ER)-mediated signaling is abolished by overexpression of a peptide that prevents the ER from forming a signaling complex necessary for rapid signaling. Carotid artery VSMCs from disrupting peptide mice or littermate wild-type female mice were obtained by the explant method. In VSMCs derived from wild-type mice, estrogen significantly inhibited VSMC proliferation. Phosphorylation levels of Akt and extracellular regulated kinase induced by platelet derived growth factor were significantly inhibited by estrogen pretreatment. Estrogen enhanced complex formation between ERα and protein phosphatase 2A (PP2), and enhanced PP2A activity. The blockade of PP2A activity abolished the estrogen-induced antiproliferative effect on VSMCs. In contrast, none of these effects of estrogen observed in the wild-type VSMCs were observed in VSMCs derived from disrupting peptide mice. These results support that rapid, non-nuclear ER signaling is required for estrogen-induced inhibition of VSMC proliferation, and further that PP2A activation by estrogen mediates estrogen-induced antiproliferative effects. CONCLUSIONS: These findings support that PP2A activation via rapid, non-nuclear ER signaling may be a novel target for therapeutic approaches to inhibit VSMC proliferation, which plays a central role in atherosclerosis and restenosis.
OBJECTIVE: The proliferation of vascular smooth muscle cells (VSMCs) plays a crucial role in vascular diseases, such as atherosclerosis and restenosis, after percutaneous coronary intervention. Many studies have shown that estrogen inhibits VSMC proliferation in response to vascular injury in the mouse carotid injury model. However, the mechanisms that mediate these effects remain unclear. Here, we investigated the mechanisms by which estrogen inhibits VSMC proliferation. APPROACH AND RESULTS: We established a novel transgenic mouse line, referred to as the disrupting peptide mice, in which rapid estrogen receptor (ER)-mediated signaling is abolished by overexpression of a peptide that prevents the ER from forming a signaling complex necessary for rapid signaling. Carotid artery VSMCs from disrupting peptide mice or littermate wild-type female mice were obtained by the explant method. In VSMCs derived from wild-type mice, estrogen significantly inhibited VSMC proliferation. Phosphorylation levels of Akt and extracellular regulated kinase induced by platelet derived growth factor were significantly inhibited by estrogen pretreatment. Estrogen enhanced complex formation between ERα and protein phosphatase 2A (PP2), and enhanced PP2A activity. The blockade of PP2A activity abolished the estrogen-induced antiproliferative effect on VSMCs. In contrast, none of these effects of estrogen observed in the wild-type VSMCs were observed in VSMCs derived from disrupting peptide mice. These results support that rapid, non-nuclear ER signaling is required for estrogen-induced inhibition of VSMC proliferation, and further that PP2A activation by estrogen mediates estrogen-induced antiproliferative effects. CONCLUSIONS: These findings support that PP2A activation via rapid, non-nuclear ER signaling may be a novel target for therapeutic approaches to inhibit VSMC proliferation, which plays a central role in atherosclerosis and restenosis.
Entities:
Keywords:
cardiovascular diseases; hormones; molecular biology; signal transduction
Authors: Derya Sivritas; Marc Ulrich Becher; Talin Ebrahimian; Omar Arfa; Stephanie Rapp; Annika Bohner; Cornelius Friedrich Mueller; Takashi Umemura; Sven Wassmann; Georg Nickenig; Kerstin Wassmann Journal: Basic Res Cardiol Date: 2011-04-12 Impact factor: 17.165
Authors: Ken L Chambliss; Qian Wu; Sarah Oltmann; Eddy S Konaniah; Michihisa Umetani; Kenneth S Korach; Gail D Thomas; Chieko Mineo; Ivan S Yuhanna; Sung Hoon Kim; Zeynep Madak-Erdogan; Adriana Maggi; Sean P Dineen; Christina L Roland; David Y Hui; Rolf A Brekken; John A Katzenellenbogen; Benita S Katzenellenbogen; Philip W Shaul Journal: J Clin Invest Date: 2010-06-23 Impact factor: 14.808
Authors: Amanda E Garza; Chevon M Rariy; Bei Sun; Jonathan Williams; Jessica Lasky-Su; Rene Baudrand; Tham Yao; Burhanuddin Moize; Wan M Hafiz; Jose R Romero; Gail K Adler; Claudio Ferri; Paul N Hopkins; Luminita H Pojoga; Gordon H Williams Journal: Hypertension Date: 2014-11-03 Impact factor: 10.190
Authors: Ken L Chambliss; Jose Barrera; Michihisa Umetani; Junko Umetani; Sung Hoon Kim; Zeynep Madak-Erdogan; Linzhang Huang; Benita S Katzenellenbogen; John A Katzenellenbogen; Chieko Mineo; Philip W Shaul Journal: Endocrinology Date: 2016-08-23 Impact factor: 4.736
Authors: Katelee Barrett Mueller; Qing Lu; Najwa N Mohammad; Victor Luu; Amy McCurley; Gordon H Williams; Gail K Adler; Richard H Karas; Iris Z Jaffe Journal: Endocrinology Date: 2014-07-22 Impact factor: 4.736